Mazzu, Ying Z. http://orcid.org/0000-0003-0265-6970
Liao, Yu-Rou
Nandakumar, Subhiksha
Jehane, Lina E.
Koche, Richard P.
Rajanala, Sai Harisha
Li, Ruifang
Zhao, HuiYong
Gerke, Travis A.
Chakraborty, Goutam
Lee, Gwo-Shu Mary
Nanjangud, Gouri J.
Gopalan, Anuradha
Chen, Yu http://orcid.org/0000-0002-0171-3884
Kantoff, Philip W. http://orcid.org/0000-0001-7275-0597
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748)
U.S. Department of Defense (W81XWH-20-1-0114, W81XWH-20-1-0114, W81XWH-20-1-0114)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 6 August 2021
Revised: 3 November 2021
Accepted: 9 November 2021
First Online: 20 November 2021
Competing interests
: As of August 5, 2021, P.W. Kantoff reports the following disclosures for the last 24-month period: he has investment interest in Cogent Biosciences, Context Therapeutics LLC, DRGT, Mirati, Placon, PrognomIQ, Seer Biosciences, SnyDevRx and XLink; he is a company board member for Context Therapeutics LLC; he is a company founder for XLink; he is co-founder and CEO of Convergent Therapeutics, he is/was a consultant/scientific advisory board member for Anji, Bavarian Nordic Immunotherapeutics, Candel, DRGT, Immunis, AI (previously OncoCellMDX), Janssen, Progenity, PrognomIQ, Seer Biosciences, SynDevRX, Tarveda Therapeutics, and Veru, and serves on data safety monitoring boards for Genentech/Roche and Merck. He reports spousal association with Bayer.